Indications and donor selections for allogeneic stem cell transplantation in children with hematologic malignancies.
Allogeneic stem cell transplantation (SCT) is the only curative approach for many patients with advanced or high-risk leukemia. Advances in supportive care and management of graft-versus-host disease have resulted in improvements in outcomes of related and unrelated donor SCT, creating controversies as to which strategy might be the optimal therapy for individual patients. This article discusses the indications and donor selection strategies for SCT in patients with malignant hematologic disease.
Handgretinger
Rupert
R
Department of Hematology/Oncology and General Pediatrics, Children's University Hospital, Hoppe-Seyler-Strasse 1, Tuebingen, Germany. rupert.handgretinger@med.uni-tuebingen.de
Kurtzberg
Joanne
J
Egeler
R Maarten
RM
D002648:Child; D006085:Graft Survival / Q000276:immunology; D019337:Hematologic Neoplasms / Q000276:immunology* / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006650:Histocompatibility Testing; D006801:Humans; D012307:Risk Factors; D019172:Transplantation Conditioning / Q000379:methods; D014181:Transplantation Immunology / Q000276:immunology; D014184:Transplantation, Homologous